Halozyme Therapeutics, Inc. Forecast, price target & analysts
Halozyme Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Halozyme Therapeutics, Inc. Classifications & Recommendation
Halozyme Therapeutics, Inc. Price Target
| Target Price | $111.86 |
| Price | $130.03 |
| Deviation | |
| Number of Estimates | 12 |
| 12 Analysts have issued a price target Halozyme Therapeutics, Inc. 2027 . The average Halozyme Therapeutics, Inc. target price is $111.86. This is lower than the current stock price. The highest price target is , the lowest is . | |
| A rating was issued by 16 analysts: 13 Analysts recommend Halozyme Therapeutics, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Halozyme Therapeutics, Inc. stock has an average upside potential 2027 of . Most analysts recommend the Halozyme Therapeutics, Inc. stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | ??? | ??? |
| ??? | ??? | |
| EBITDA Margin | ??? | ??? |
| ??? | ??? | |
| Net Margin | ??? | ??? |
| ??? | ??? |
11 Analysts have issued a sales forecast Halozyme Therapeutics, Inc. 2026 . The average Halozyme Therapeutics, Inc. sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
8 Analysts have issued an Halozyme Therapeutics, Inc. EBITDA forecast 2026. The average Halozyme Therapeutics, Inc. EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
11 Halozyme Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Halozyme Therapeutics, Inc. net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | ??? | ??? |
| ??? | ??? | |
| P/E | ??? | |
| EV/Sales | ??? |
11 Analysts have issued a Halozyme Therapeutics, Inc. forecast for earnings per share. The average Halozyme Therapeutics, Inc. EPS is
. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .This results in the following potential growth metrics and future valuations:
Halozyme Therapeutics, Inc....
Current Halozyme Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| Analyst Rating | Date |
|---|---|
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
